AN ADAPTIVE, OPEN-LABEL, DOSE-FINDING, PHASE 1/2 STUDY INVESTIGATING THE SAFETY, PHARMACOKINETICS, AND CLINICAL ACTIVITY OF RILZABRUTINIB (PRN1008), AN ORAL BTK INHIBITOR, IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA
- Registry ID
- PRN1008-010 (DFI17124)
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- PRINCIPIA BIOPHARMA INC
- Start date
- 2022-01-14
- Completion date
- 2025-12-11
- Last update
- 2019-02-21
Conditions
- IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
View on source registry